Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
2
×
clinical trials
drugs
2
×
fda
life sciences
national blog main
acute hepatic porphyrias
akin akinc
alder biopharmaceutical
allergan
alnylam pharmaceuticals
american academy of neurology
amgen
aminolevulinic acid
atogepant
biohaven
biotech
bob azelby
boston
botox
boulder/denver blog main
boulder/denver top stories
brian abrahams
calcitonin gene-related peptide
detroit blog main
detroit top stories
eli lilly
eptinezumab
erenumab
fremanezumab
galcanezumab
givosiran
impel neuropharma
indiana blog main
indiana top stories
jefferies
lasmiditan
marc goodman
medical device
What
approval
2
×
drug
2
×
fda
ago
alnylam
arguments
big
class
commercialized
companies
competitors
decades
drugs
indicated
interference
make
medicine
meeting
migraine
neuro
new
nod
oral
pharmaceuticals
potential
quick
rna
rnai
second
seek
speedy
therapies
weeks
won
won’t
year
Language
Current search:
drug
×
drugs
×
" boston top stories "
×
approval
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug